834 related articles for article (PubMed ID: 23384837)
1. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
2. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
Pollastrini J; Dillon TM; Bondarenko P; Chou RY
Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
[TBL] [Abstract][Full Text] [Related]
3. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
4. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
5. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
6. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
7. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
8. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
9. Albumin binding to FcRn: distinct from the FcRn-IgG interaction.
Chaudhury C; Brooks CL; Carter DC; Robinson JM; Anderson CL
Biochemistry; 2006 Apr; 45(15):4983-90. PubMed ID: 16605266
[TBL] [Abstract][Full Text] [Related]
10. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization.
Vaughn DE; Bjorkman PJ
Biochemistry; 1997 Aug; 36(31):9374-80. PubMed ID: 9235980
[TBL] [Abstract][Full Text] [Related]
11. Identification of critical IgG binding epitopes on the neonatal Fc receptor.
Vaughn DE; Milburn CM; Penny DM; Martin WL; Johnson JL; Bjorkman PJ
J Mol Biol; 1997 Dec; 274(4):597-607. PubMed ID: 9417938
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
13. Development of new models for the analysis of Fc-FcRn interactions.
Gurbaxani BM; Morrison SL
Mol Immunol; 2006 Mar; 43(9):1379-89. PubMed ID: 16183124
[TBL] [Abstract][Full Text] [Related]
14. A strategy for bacterial production of a soluble functional human neonatal Fc receptor.
Andersen JT; Justesen S; Berntzen G; Michaelsen TE; Lauvrak V; Fleckenstein B; Buus S; Sandlie I
J Immunol Methods; 2008 Feb; 331(1-2):39-49. PubMed ID: 18155020
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.
Martin WL; West AP; Gan L; Bjorkman PJ
Mol Cell; 2001 Apr; 7(4):867-77. PubMed ID: 11336709
[TBL] [Abstract][Full Text] [Related]
16. Development and applications of AlphaScreen-based FcRn binding assay to characterize monoclonal antibodies.
Wu Q; Lee HY; Wong PY; Jiang G; Gazzano-Santoro H
J Immunol Methods; 2015 May; 420():31-7. PubMed ID: 25837414
[TBL] [Abstract][Full Text] [Related]
17. Multiple roles for the major histocompatibility complex class I- related receptor FcRn.
Ghetie V; Ward ES
Annu Rev Immunol; 2000; 18():739-66. PubMed ID: 10837074
[TBL] [Abstract][Full Text] [Related]
18. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
[TBL] [Abstract][Full Text] [Related]
19. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand.
Sánchez LM; Penny DM; Bjorkman PJ
Biochemistry; 1999 Jul; 38(29):9471-6. PubMed ID: 10413524
[TBL] [Abstract][Full Text] [Related]
20. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
